Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Endpoints Magazine webinar on OV 08 November 23
View:
Post by askretka on Oct 09, 2023 8:05am

Endpoints Magazine webinar on OV 08 November 23

https://ci5.googleusercontent.com/proxy/DmuFhn3GTX7S-QdEVwV4VoK7-zAoFHlHfAu-cY6MLqK40u2agfroaruLxxVBbtwO9Y-4RoZbbB2MRm5TeJbWugQbtC4rnALNKaiZJD4Jhim-1KyX38WN9Sd6i34ELlMfDCqxXtszAQWcGmSqogoR=s0-d-e1-ft#https://i6.cmail20.com/ei/t/A5/DF1/CB9/220205/csimport/384ac740dea885357cf3c904202ebfdb_5.jpg


Cheers!!!!!!
Comment by Noteable on Oct 09, 2023 9:26am
Also -  Re-activating the immune system against cancer: The next I-O revolution https://webinars.endpts.com/
Comment by askretka on Oct 09, 2023 10:07am
It's been quite awhile since Endpoints Magazine has shown OV therapies any love. I'm pretty sure I already known what they are going to say. More coverage is always welcomed though. That Checkpoints and CAR-T have re invigorated interest in OV's as combination therapies.  But I'll probably tune in if I have time hopefully.  Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! ...more  
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities